Scientific Publications

Advancing dermatological science.

September 2021

EADV 2021

Roflumilast Foam 0.3%, Safety and Efficacy in Patients with Seborrheic Dermatitis
Read More

July 2021

Dermatology and Therapy

Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
Read More

May 2021

EADV Spring Symposium 2021

Roflumilast Cream, Safety and Efficacy in two Ph3 Studies (DERMIS-1 and DERMIS-2) in Patients with Chronic Plaque Psoriasis
Read More

April 2021

AAD 2021

Roflumilast Cream, Correlation of Itch and Disease Severity in Adults with Chronic Plaque Psoriasis, Ph2b Study
Read More

April 2021

AAD 2021

Roflumilast Foam, Safety and Efficacy in Patients with Scalp and Body Psoriasis, Ph2b Study
Read More

April 2021

AAD 2021

Roflumilast Foam, Safety and Efficacy in Patients with Seborrheic Dermatitis, Ph2 Study
Read More

April 2021

AAD 2021

Roflumilast Cream, Safety and Efficacy in Steroid-sensitive Areas in Adults with Chronic Plaque Psoriasis, Ph2b Study
Read More

April 2021

AAD 2021

PASI-HD Improved Precision in Measuring Disease Severity in Patients with Mild to Moderate Plaque Psoriasis Treated with Roflumilast Cream, Ph2b Study
Read More

March 2021

Innovations in Dermatology 2021

Roflumilast Cream, Long-term Safety and Efficacy in a Ph2b Study in Adults with Chronic Plaque Psoriasis
Read More

October 2020

EADV, Fall Clinical, SDPA 2020

Roflumilast Cream, Improved Patient Burden of Signs and Symptoms in Adults with Chronic Plaque Psoriasis, Ph2b study
Read More

October 2020

EADV, Fall Clinical, SDPA 2020

Roflumilast Cream, Improved Itch Severity and Itch-related Sleep Loss in Adults with Chronic Plaque Psoriasis, Ph2b study
Read More

October 2020

EADV, Fall Clinical, SDPA 2020

Roflumilast Cream, Safety and Efficacy in a Ph2 Proof-of-Concept study in Adults with Atopic Dermatitis
Read More

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download